According to the Oral Cancer Foundation, Adenoid cystic carcinoma (ACC) is a form of malignant neoplasm that arises within secretory glands, most commonly the major and minor salivary glands of the head and neck. Other sites of origin include the trachea, lacrimal gland, breast, skin, and vulva.
Adenoid Cystic Carcinoma (ACC) Market key facts
A review titled “Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling” by Chae et al. stated that the age-adjusted incidence rate of head and neck ACC is 4.5 cases per 100,000 individuals, occurring with a slight female predominance (60% vs. 40% in males).
A review by Berardinis et al. titled “Adenoid Cystic Carcinoma of Head and Neck” stated that the ACC has a global incidence of 3–4.5 cases per million per year.
DelveInsight's "Adenoid Cystic Carcinoma (ACC) Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the Adenoid Cystic Carcinoma (ACC) Market, historical and forecasted epidemiology, the pipeline insight as well as the Adenoid Cystic Carcinoma (ACC) market size and shares analysis in the seven major markets (7MM) (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Adenoid Cystic Carcinoma (ACC) Market Analysis
The Adenoid Cystic Carcinoma (ACC) market analysis section of the report helps to build the detailed comprehension of the historic, current, and forecasted Adenoid Cystic Carcinoma (ACC) market trends and growth by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Adenoid Cystic Carcinoma (ACC) market size and shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Adenoid Cystic Carcinoma (ACC) Epidemiology Forecast
The Adenoid Cystic Carcinoma (ACC) epidemiology section covers insights about historical and current Adenoid Cystic Carcinoma (ACC) patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Adenoid Cystic Carcinoma (ACC) Pipeline Analysis and Key Companies
The Adenoid Cystic Carcinoma (ACC) Pipeline and Drugs Uptake section focus on the rate of uptake of the potential drugs recently launched in the Adenoid Cystic Carcinoma (ACC) market or expected to get launched in the market during the study period. The analysis covers the Adenoid Cystic Carcinoma (ACC) market uptake by drugs; patient uptake by therapies; and sales of each drug.
Some of the key companies in the Adenoid Cystic Carcinoma (ACC) market includes:
Cellestia Biotech
Ayala
CureVac
And others.
Adenoid Cystic Carcinoma (ACC) Therapies covered: CB-103, AL101, and many others.
Source: Adenoid Cystic Carcinoma (ACC) Therapeutics Market